Psoriatic Arthritis Clinical Trials

82 recruitingLast updated: June 17, 2026

There are 82 actively recruiting psoriatic arthritis clinical trials across 49 countries. Studies span Not Applicable, Phase 3, Phase 2, Phase 1, Phase 4. Top locations include Berlin, Germany, Hamburg, Germany, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Psoriatic Arthritis Trials at a Glance

82 actively recruiting trials for psoriatic arthritis are listed on ClinicalTrialsFinder across 6 cities in 49 countries. The largest study group is Not Applicable with 15 trials, with the heaviest enrollment activity in Berlin, Hamburg, and Houston. Lead sponsors running psoriatic arthritis studies include AbbVie, UCB Biopharma SRL, and Takeda.

Browse psoriatic arthritis trials by phase

Treatments under study

About Psoriatic Arthritis Clinical Trials

Looking for clinical trials for Psoriatic Arthritis? There are currently 54 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Psoriatic Arthritis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Psoriatic Arthritis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 82 trials

Recruiting
Phase 2

Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)

Psoriatic Arthritis
Merck Sharp & Dohme LLC140 enrolled43 locationsNCT07486960
Recruiting
Phase 1

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting
Phase 3

A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

Juvenile Psoriatic Arthritis
Bristol-Myers Squibb60 enrolled47 locationsNCT06869551
Recruiting
Phase 4

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

Psoriatic ArthritisOverweight or Obesity
Eli Lilly and Company200 enrolled55 locationsNCT06864026
Recruiting
Not Applicable

Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy

Psoriatic Arthritis
University of California, San Diego20 enrolled1 locationNCT06586281
Recruiting
Phase 1

A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

Psoriatic ArthritisAxial Spondyloarthritis
UCB Biopharma SRL392 enrolled61 locationsNCT07290036
Recruiting
Phase 3

An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Enthesitis Related ArthritisJuvenile Psoriatic Arthritis
UCB Biopharma SRL40 enrolled23 locationsNCT06668181
Recruiting
Not Applicable

Modifying PEST for Psoriatic Arthritis Screening

Psoriatic ArthritisPlaque Psoriasis
Novartis Pharmaceuticals502 enrolled29 locationsNCT06382051
Recruiting
Phase 1

Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).

Juvenile Psoriatic Arthritis
Novartis Pharmaceuticals20 enrolled8 locationsNCT06751238
Recruiting
Phase 3

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

Psoriatic Arthritis
Takeda1,088 enrolled189 locationsNCT06671483
Recruiting
Phase 1

Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease

Psoriatic Arthritis (PsA)Rheumatoid Arthritis (RA)Psoriasis (PsO)+3 more
Seismic Therapeutic AU Pty Ltd24 enrolled2 locationsNCT07455578
Recruiting
Not Applicable

Cytokine Expression in Psoriasis Patients With and Without Joint Involvement

PsoriasisPsoriatic Arthritis
Poitiers University Hospital40 enrolled1 locationNCT05307809
Recruiting
Phase 4

Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER)

Psoriatic Arthritis (PsA)AtherosclerosisRheumatoid Arthritis (RA)+4 more
Instituto de Investigación Marqués de Valdecilla1,944 enrolled17 locationsNCT07611747
Recruiting

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

MelanomaRheumatoid ArthritisAnkylosing Spondylitis+10 more
M.D. Anderson Cancer Center125 enrolled1 locationNCT04751396
Recruiting
Phase 3

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

Juvenile Psoriatic Arthritis
AbbVie40 enrolled32 locationsNCT06100744
Recruiting
Phase 2

A Study of SPY072 in Rheumatic Disease

Rheumatoid ArthritisPsoriatic ArthritisRheumatic Diseases+5 more
Spyre Therapeutics, Inc.285 enrolled64 locationsNCT07148414
Recruiting
Phase 1

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

Hidradenitis SuppurativaPsoriatic ArthritisAxial Spondyloarthritis+1 more
UCB Biopharma SRL20 enrolled12 locationsNCT06888193
Recruiting
Not Applicable

Deployment o the Multidisciplinary Prospective Cohort Imminent

Severe AsthmaMultiple SclerosisAtopic Dermatitis+6 more
University Hospital, Lille2,200 enrolled1 locationNCT04334031
Recruiting
Not Applicable

Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis

Obesity, OverweightPsoriatic Arthritis (PsA)
NHS Greater Glasgow and Clyde45 enrolled4 locationsNCT07443956
Recruiting
Phase 3

A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

Psoriatic ArthritisModerate to Severe Plaque Psoriasis
UCB Biopharma SRL90 enrolled16 locationsNCT06506916